Sonova Holding AG SOON

Morningstar Rating
CHF 315.40 −0.80 (0.25%)
View Full Chart

Company Report

Growth Returns for Sonova

Sonova benefits from favorable trends, including an aging population, increasing noise pollution, fairly low penetration rates for hearing aids in the developed world, and virtually untapped patient populations in emerging markets. Its broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains.

Price vs Fair Value

SOON is trading at a 847% premium.
Price
CHF 315.40
Fair Value
CHF 541.00
Uncertainty
Medium
1-Star Price
CHF 988.60
5-Star Price
CHF 457.50
Economic Moat
Gskfn
Capital Allocation
Cczlqgjy

Bulls Say, Bears Say

Bulls

Premium products account for a significant portion of Sonova's total revenue, limiting the firm's dependence on price-sensitive economy-class systems.

Bears

WS Audiology (previously Sivantos and Widex) is regaining momentum, particularly in emerging markets. Its acquisition of Widex could threaten the positioning of premium providers.

News

Trading Information

Previous Close Price
CHF 316.20
Day Range
CHF 313.00316.50
52-Week Range
CHF 205.80316.50
Bid/Ask
CHF 310.00 / CHF 0.00
Market Cap
CHF 18.80 Bil
Volume/Avg
154,187 / 139,521

Key Statistics

Price/Earnings (Normalized)
26.93
Price/Sales
5.20
Dividend Yield (Trailing)
1.36%
Dividend Yield (Forward)
1.36%
Total Yield
1.53%

Company Profile

Sonova is one of the world's largest manufacturers and distributors of hearing aids. The company is based in Switzerland and distributes its products in more than 100 countries through its internal sales team and independent retailers. It also sells cochlear implants through its advanced bionics subsidiary and recently acquired Sennheiser's consumer division to expand into audio technologies.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Core
Total Number of Employees
18,151

Competitors

Valuation

Metric
SOON
DEMANT
GN
Price/Earnings (Normalized)
26.9322.0517.27
Price/Book Value
7.616.112.10
Price/Sales
5.202.581.17
Price/Cash Flow
24.0614.258.13
Price/Earnings
SOON
DEMANT
GN

Financial Strength

Metric
SOON
DEMANT
GN
Quick Ratio
1.020.750.47
Current Ratio
1.451.420.68
Interest Coverage
23.786.324.20
Quick Ratio
SOON
DEMANT
GN

Profitability

Metric
SOON
DEMANT
GN
Return on Assets (Normalized)
10.91%8.21%1.95%
Return on Equity (Normalized)
26.88%27.51%6.04%
Return on Invested Capital (Normalized)
17.63%12.10%3.45%
Return on Assets
SOON
DEMANT
GN

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
WtkcfhjfPqpjy$196.0 Bil
Stryker Corp
SYK
CtcxflgmRfkz$133.8 Bil
Boston Scientific Corp
BSX
NhkrftwkXtjrcc$124.5 Bil
Medtronic PLC
MDT
XjhczrcbLqrmcn$113.2 Bil
Edwards Lifesciences Corp
EW
SrrqjfkxxbHphmpb$39.5 Bil
Koninklijke Philips NV ADR
PHG
FsvnDnchn$30.2 Bil
DexCom Inc
DXCM
QmrnjjyjVfs$27.3 Bil
Steris PLC
STE
KhnrlszRykbkd$22.8 Bil
Zimmer Biomet Holdings Inc
ZBH
VqgtrygdCwz$21.3 Bil
Insulet Corp
PODD
MtpjplkpBgpktm$16.1 Bil

Sponsor Center